Aromasin 25 mg coated tablets clinical trials

C4391022 - AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR’S CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY

This study looks at a new drug (PF-07220060) combined with a standard breast cancer treatment (Fulvestrant). It's for advanced hormone receptor-positive, HER2-negative breast cancer that has grown after previous CDK 4/6 inhibitor treatment. Researchers want to see if the new combination works better.